Skip to main content

Recombinant Human Fc mu R/FAIM3 Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 9494-MU

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
9494-MU-050

Key Product Details

Source

HEK293

Accession #

Conjugate

Unconjugated

Applications

Bioactivity

Product Specifications

Source

Human embryonic kidney cell, HEK293-derived human Fc mu R/FAIM3 protein
Human Fc mu R/FAIM3
(Arg18-Gly251)
Accession # O60667-1
HisHis  HA
(YPYDVPDYA)
N-terminus C-terminus

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Arg18

Predicted Molecular Mass

27 kDa

SDS-PAGE

39-50 kDa, reducing conditions

Activity

Measured by its binding ability in a functional ELISA.
When human IgM is immobilized at 2 μg/mL, 100 μL/well, Recombinant Human Fc mu R/FAIM3 binds with an ED50 of 0.4-2 μg/mL.

Scientific Data Images for Recombinant Human Fc mu R/FAIM3 Protein, CF

Recombinant Human Fc mu R/FAIM3 Protein Bioactivity

Recombinant Human Fc mu R/FAIM3 Protein Bioactivity

When human IgM is immobilized at 2 μg/mL, 100 μL/well, Recombinant Human Fc mu R/FAIM3 (Catalog # 9494-MU) binds with an ED50 of 0.4-2 μg/mL.

Formulation, Preparation and Storage

9494-MU
Formulation Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Reconstitution
Reconstitute at 200 μg/mL in PBS.

Reconstitution Buffer Available:
Size / Price
Qty
Loading...
Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: Fc mu R/FAIM3

The human FAIM3 gene (also known as FCMR or TOSO), is a transmembrane sialoglycoprotein expressed mainly by lymphocytes. FAIM3 is a type I membrane protein with an intracellular C-terminal domain and an extracellular N-terminal domain (1). The extracellular domain has homology to the immunoglobulin variable region domains (1) and FAIM3 is identified as an Fc receptor for IgM (2, 3). The amino acid sequence of human FAIM3 is 58% and 55% identical to that of mouse and rat FAIM3, respectively. FAIM3 was shown to be over-expressed in chronic lymphocytic leukemia (CLL) (4) and associated with disease progression (5, 6). FAIM3 has also been linked to the homeostasis and activation of the innate immune system (7). Interestingly, there is growing evidence that neurodegenerative diseases are associated with the activation of the immune surveillance system. This system is responsible for controlling danger signals and responding accordingly to the magnitude and duration of the threat (8, 9).

References

  1. Song, Y. et al (2005) J. Biol. Chem. 280(10):9618.
  2. Shima H et al. (2010) Int. Immunol. 22:149.
  3. Kubagawa H et al. (2009) J. Exp. Med. 206:2779.
  4. Proto-Siqueira R et al. (2008) Blood, 112:394.
  5. Pallasch, C et al. (2008) Blood, 112:4213.
  6. Pallasch, C P et al (2009) Leukemia & lymphoma, 50:498.
  7. Sigruener, A et al (2007) Biochemical and biophysical research communications, 359:723.
  8. Richards R I et al (2016) Front. Neurosci. 10:193.
  9. Planells-Ferrer L et al (2016) J Neurochem. 139:11.

Long Name

Fc mu Receptor

Alternate Names

FAIM3, FCMR, Toso

Entrez Gene IDs

9214 (Human); 69169 (Mouse); 548326 (Rat)

Gene Symbol

FCMR

UniProt

Additional Fc mu R/FAIM3 Products

Product Documents for Recombinant Human Fc mu R/FAIM3 Protein, CF

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Recombinant Human Fc mu R/FAIM3 Protein, CF

For research use only

Loading...
Loading...
Loading...